RGLS slammed AH -54%, clinical hold,
it's their second SAE, not for me no no, so bounce players should be good to go.
Regulus Therapeutics Inc. (Nasdaq:RGLS) shares slumped more than 50% to touch a new 52-week low in the extended session Monday as the biopharmaceutical company said that the U.S. Food and Drug Administration (FDA) has placed on clinical hold its Investigational New Drug (IND) for RG-101 – Regulus’ treatment for chronic HCV infection
RGLS stock closed in negative territory by 5.29% (or -$0.28) at $5.01 and 1.35M of its shares changed hands during the day, a large increase in activity versus its average volume (3m) of 794,360
Regulus Therapeutics, which focuses on discovering and developing drugs that target microRNAs to treat a range of diseases, has 52.78M Shares Outstanding. At close on Monday, the company had a Market Capitalization $243.70M and RGLS stock one-year range was from $4.82 to $5.35 per share
